• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics Inc (NQ: DYN )

    32.58 -0.97 (-2.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,240,269
    Open 34.00
    Bid (Size) 32.04 (1)
    Ask (Size) 34.63 (2)
    Prev. Close 33.55
    Today's Range 32.39 - 34.00
    52wk Range 6.400 - 47.45
    Shares Outstanding 58,310,703
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Peering Into Dyne Therapeutics's Recent Short Interest
    Via Benzinga
    Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +149.46%
    +149.46%
    1 Month
    +2.00%
    +2.00%
    3 Month
    -5.29%
    -5.29%
    6 Month
    +23.18%
    +23.18%
    1 Year
    +292.06%
    +292.06%

    More News

    Read More
    Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
    From Kirby McInerney LLP
    Via Business Wire
    DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
    Via Benzinga
    Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
    Via Investor's Business Daily
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nasdaq Dips Over 2%; US Construction Spending Falls In July
    Via Benzinga
    Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Dyne Therapeutics Announces Key Leadership Appointments
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    Via Benzinga
    Chart Of The Day: Dyne Therapeutics - Deeply Discounted
    Via Talk Markets
    Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.